

# PATIENT INFORMATION & CONSENT FORM

Service (please select Service ordered)



FOUNDATIONONE® CDx



FOUNDATIONONE® HEME



FOUNDATIONONE® LIQUID CDx

## Patient Information and Declaration of Consent to the Processing of Personal Data

Your treating physician has recommended performing a molecular genetic test for diagnostic purposes to analyse your blood (which may include bone marrow) and/or tissue specimen (as required for your test) in order to detect gene mutations specific to your tumour. The appropriate diagnostic test (FoundationOne CDx, FoundationOne Heme or FoundationOne Liquid CDx) was selected by your physician and is indicated at the top of this document ("Service").

The Service is provided to you by Roche in conjunction with Foundation Medicine as set out below:

- The Service is offered in your country by Roche Products Limited ("Local Roche Affiliate") which is the contracting party for the performance of the Service, handling local coordination and customer support. The Local Roche Affiliate is responsible for the processing of any personal data received from you in the context of providing the Service as joint controller together with Roche Pharma AG, Emil-Barell-Straße 1, 79639 Grenzach, Germany ("Roche Pharma AG"). Roche Pharma AG handles the central coordination and quality of the Service provision in Europe and is also responsible for providing customer support. The Local Roche Affiliate and Roche Pharma AG are hereinafter, collectively, referred to as "Roche". Roche can be contacted at the contact details set out in Section 3 below.
- To provide the Service, Roche collaborates with Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany ("FMI GmbH") which – as joint controller together with Foundation Medicine Inc., 150 Second Street, Cambridge, MA 02141, USA ("FMI Inc.") – conducts the molecular genetic services. FMI GmbH and FMI Inc. will jointly process your personal data on systems and applications operated by FMI Inc. In most cases, FMI GmbH will carry out the main data processing activities in the context of providing the laboratory services for the applicable test and FMI Inc. will assist only with certain parts of the Service, as further explained below. Only in the case of: (1) an order for the FoundationOne Liquid CDx Service before the time when FMI GmbH will carry out the laboratory services for this test or (2) in those limited instances set out in Section 1.D below, will your data be transferred by your treating physician and/or Roche directly to FMI Inc. in the US. FMI Inc. will then be primarily responsible for carrying out all of the FoundationOne Liquid CDx test (without or with only limited involvement of FMI GmbH). FMI GmbH and FMI Inc. are hereinafter, collectively, referred to as "FMI". FMI can be contacted at the contact details set out in Section 3 below.

This Patient Information and Declaration of Consent ("Patient Consent Form") informs you about the processing of your personal data by your treating physicians, Roche and FMI and serves as the basis for obtaining and documenting your consent to the processing of your personal data.

## Section 1 (Required Consent) –

### Consent to the Processing of your Personal Data for the Purpose of Providing the Service

Your consent to the processing of your personal data pursuant to this Section 1 is required to provide the requested Service. To give your consent, please provide your signature at the end of this form.

#### A. Assignment of Order ID by Roche (Pseudonymisation Process)

Roche will review your physician's order and assign an Order-ID to your case if the contract is accepted. Roche will make that Order-ID available to your treating physician, your pathologist and FMI, as required to provide the Service to you.

The Order-ID is a unique central identifier of your case that does not reveal your identity but allows your treating physicians and pathologist to exchange data on your case with Roche and FMI in pseudonymised form. This means that even though Roche and FMI may receive data with specific characteristics about you, including your health-related information, they are generally not able to trace those characteristics back to you, except in cases where your treating physician or pathologist reveals your identity. Under no circumstances will FMI receive any information to attribute the Order-ID to your person.

#### B. Preparation of Specimen by Pathologist (if applicable)

To prepare your tissue specimen (as required for your Service), your treating physician will cooperate with the pathologist who has access to your specimen and exchange with that pathologist the data which are relevant for the diagnostic Service (e.g. diagnosis and date of birth), including, if necessary, the complete patient file.

---

#### Roche Products Limited

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW,  
Registered in England 100674  
medinfo.uk@roche.com

Roche Products Limited is the sole licensed distributor of Foundation Medicine, Inc. products in the UK

M-GB-000001765 November 2020

## C. Laboratory Analysis and Report Creation by FMI

To start the provision of the Service, your treating physician or pathologist will complete a test requisition form with the below pseudonymous data (together the “**Test Requisition Form Data**”) and provide it to Roche and FMI:

- Order-ID
- Date of birth (day/month/year)
- Gender
- Diagnosis, stage
- Specimen site
- Specimen-ID (identifier of the blood/tissue specimen)
- Date of specimen collection
- International classification of the disease (ICD-10 Code)
- Status of transplant
- Contact information of your treating physician and pathologist
- Not mandatory: Pathology report (in redacted form)

The treating physician or pathologist may provide the pathology report (in redacted form) where more detailed diagnosis and sample information could be helpful for the provision of the Service.

In addition, the treating physician or pathologist may provide through the test requisition form a unique identification number (such as a patient reference number). This number will not be further used by Roche or FMI, but only printed on the test report as this should help your treating physician or pathologist directly identify you and assign the report to you more efficiently.

The FMI laboratory site carrying out the laboratory services for the applicable test (i.e. either FMI GmbH or FMI Inc.) will receive your Test Requisition Form Data, depending on the order process, from either Roche or directly from your treating physician or pathologist. The Test Requisition Form Data will be stored and jointly processed by FMI Inc. and FMI GmbH on systems and applications operated by FMI Inc. in the US.

In parallel, your treating physician or pathologist will send your blood and/or tissue specimen (as required for your Service and described in Section 1.C above), to the same FMI laboratory site.

Except where you have provided your optional consent to the processing of your personal data for research and scientific purposes (as set out in Section 2 below), FMI will process the Test Requisition Form Data only for the purpose of providing the requested diagnostic Service, that is to:

- confirm receipt of the correct specimen
- assess a pathology review (confirm disease ontology and assess tumour content) by employed or freelance pathologists and scan the tissue slide;
- extract the DNA/RNA and sequence the relevant cancer genes that are associated with tumour genesis and tumour progression; and
- analyse the obtained genomic data for gene mutations, match the data of specific mutations with targeted therapies and ongoing clinical studies and prepare the report on the identified gene mutations and available therapy options. It cannot be guaranteed that there will be any available therapy options.

FMI will involve external pathologists located in Germany who will be granted access to your report to verify and release the final report, as required for internal quality assurance and compliance with regulatory requirements. The report will then be transferred to your treating physician and pathologist and, if applicable, further recipients named by your hospital, clinic or other medical facility who will be involved in your treatment and need to have access to the report as a basis for a decision on your future therapy. Your report may also be further made available to other appropriate teams at FMI Inc. for treatment purposes, including for example in the context of a Molecular Tumour Board.

Other than as necessary to provide the requested Service, FMI will not further analyse or process your DNA/RNA. The genomic data obtained during the sequencing analysis by FMI will not contain any directly personal identifiable data. For the avoidance of doubt, Roche does not have access to your DNA/RNA.

The joint processing of your pseudonymised personal data by FMI GmbH and FMI Inc. takes place on systems and applications operated by FMI Inc. In most cases of the Service: (1) FMI GmbH will carry out the laboratory service for the applicable test and be responsible for the processing of your Test Requisition Form Data and your blood and/or tissue specimen (as required for your Service) in relation to the extraction of DNA/RNA and sequencing of relevant genes and (2) FMI Inc. will have access to and process such pseudonymised information (with the exception of the blood/tissue specimen and the extracted DNA/RNA) as necessary for the analysis of the obtained genomic data, matching potential therapies and clinical trials to the identified mutations, and creation of your test report. In exceptional cases where FMI GmbH is unable to carry out the steps in (1) above, FMI Inc. will perform these steps in order to ensure business continuity and your blood/tissue specimen and the extracted DNA/RNA will be transferred to FMI Inc.

Only in the case of an order of the Service FoundationOne Liquid CDx or those exceptional cases described above, will your pseudonymised data be transferred by Roche and/or your treating physician or pathologist directly to FMI Inc. in the US. FMI Inc. will then carry out all of the above steps (without or with only limited involvement of FMI GmbH). Until such time as FMI GmbH is able to perform the laboratory services portion of the FoundationOne Liquid CDx test, FMI Inc. will receive your blood specimen for FoundationOne Liquid CDx testing. After such time, FMI GmbH will receive your blood specimens to conduct the service. For more details about the roles of FMI GmbH and FMI Inc. in the context of your specific Service, please contact your treating physician or FMI at the contact details set out in Section 3 below.

---

### Roche Products Limited

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW,  
Registered in England 100674  
medinfo.uk@roche.com

Roche Products Limited is the sole licensed distributor of Foundation Medicine, Inc. products in the UK

As necessary to provide the Service, and where you have provided your optional consent to the processing of your data for research and scientific purposes (as set out in Section 2 below), your pseudonymised data (e.g., Test Requisition Form Data and, as applicable, your blood specimen and, in exceptional cases, tissue specimen) will be transmitted to FMI Inc. in the US, and thus to a country outside the EU/EEA, the laws of which may not provide for the same level of data protection as considered adequate in the European Union. This triggers certain risks for the protection of your personal data, including that it may be more difficult to enforce your data protection rights as a data subject and that your pseudonymised personal data may be subject to access requests under applicable US law by public authorities who may have more extensive powers than the authorities in the EU/EEA. To ensure that your data are adequately protected as required by EU data protection laws, Roche and FMI have entered into contractual safeguards on the basis of the EU Standard Contractual Clauses (according to Art. 46 GDPR) between FMI GmbH and FMI Inc. as well as between Roche Pharma AG and FMI Inc. and have implemented further supplementary measures, including a privacy by design concept that ensures that only pseudonymised data will be transferred to FMI Inc. in the US. To the extent your pseudonymised data is transferred to FMI Inc. directly by your treating physician or pathologist, such as in the case of an order for the Service FoundationOne Liquid CDx, FMI Inc. will protect the data received equally under the EU Standard Contractual Clauses entered into with FMI GmbH and Roche.

As necessary to provide the Service, FMI may engage technical service providers as processors for the hosting and operation of its databases, portals and applications. These service providers may be located in the EU/EEA or the US. In the case of service providers in the US, FMI will ensure that appropriate safeguards are in place to provide for an adequate level of data protection, such as by entering into data transfer agreements with the applicable service provider on the basis of the EU Standard Contractual Clauses, or standard data protection clauses adopted or approved by the European Commission (Art. 46 GDPR).

You can find out more information about the safeguards implemented by FMI, including how to obtain a copy of them, by contacting FMI at the contact details set out at Section 3 below.

As an additional safeguard, in all of the above cases, FMI and its further subcontractors only store and process pseudonymised information which is not directly attributable to your person. To the extent FMI accidentally receives data in fully personal identifiable form from your treating physician or pathologist (such as your name in a pathology report), FMI will redact such information upon receipt. FMI will, however, also be provided with your blood and/or tissue specimen (as required for your Service), which contains your DNA/RNA and, therefore, your unique genetic fingerprint. FMI will not sequence and process your data to obtain your genetic fingerprint. Any report provided to Roche will also be free of such information.

## **D. Central Coordination of Services, Quality of Service Provision and Customer Service by Roche**

Roche will manage access to the Test Requisition Form and make it available to FMI. If FMI notifies Roche of missing or inaccurate data in a Test Requisition Form, Roche will work with the pathologist and treating physicians to correct the data set. Roche will also track the status of the provision of the Service on the basis of the Order-ID. Roche's processing is for the purpose of central coordination of the Service in Europe, ensuring the quality of the Service provision, and handling of customer service requests. To the extent necessary for these purposes, Roche receives the relevant information from the pathologist (Test Requisition Form Data) and FMI (Test Requisition Form Data, information about status of Service) but in any case with the exception of the blood/tissue specimen, obtained sequencing data and DNA/RNA.

In addition, to the extent necessary to handle report-specific questions from your treating physicians, Roche may also have access to the report stored at FMI. Roche and FMI will ensure by implementing appropriate technical and organisational measures that access to the report will only be made on a case-by-case basis, upon receipt of a support request and to the extent required to fulfil the support request, for example, to provide the treating physician with information, where the report has not been provided to the physician or if your treating physicians have report-specific questions.

## **E. Term of Storage; Deletion**

Roche will store and retain your data in accordance with the following processes:

- The data specified in Sections 1 A, 1 D, and 1 E above will be stored by Roche in productive systems for 90 days starting from the date of the release of the test report to your treating physician ("Completion of the Service"), then archived for 10 years and will be deleted thereafter.

Except where you have provided your consent to the processing of your data for research and scientific purposes (as described under Section 2), FMI will store your data and residual material only for as long as necessary to provide the Service and for the purpose of providing a physical audit trail, in case the integrity or identification of the specimen needs to be established, in accordance with the following processes:

- **Blood/Tissue Specimen:** After Completion of the Service, or where the Service ends because you withdraw your consent, any tissue specimen not used up by FMI (if any under the requested Service) will, if available in the form of a tumour block, be returned by FMI to the pathologist. Slide return is available upon written request. Remaining slides will be stored for 10 years and extracted DNA/RNA will be stored at FMI for a maximum of 1 year and, in each case, discarded thereafter (all starting from the Completion of the Service). Blood specimens will be discarded by FMI once no longer required for the Service and at the latest upon Completion of the Service.

- **Test Requisition Form Data & Report:** The Test Requisition Form Data (see Section 1 D above) and the report will be stored by FMI GmbH for a maximum of 10 years after the Completion of the Service and discarded thereafter. In cases where the Test Requisition Form Data as well as the specimen is sent directly to FMI Inc., both the data and report will be stored by FMI Inc. for a maximum of 10 years after the Completion of the Service.

---

### **Roche Products Limited**

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW,  
Registered in England 100674  
medinfo.uk@roche.com

Roche Products Limited is the sole licensed distributor of Foundation Medicine, Inc. products in the UK

**- Scanned Tissue Slides and Sequenced Tumour Genome:** The scanned tissue slides and the obtained sequencing raw data will be stored at FMI Inc. for a maximum of 10 years after the Completion of the Service and discarded thereafter. Curated sequencing data will be stored for a maximum of 10 years after the Completion of the Service and discarded thereafter.

Your personal data will be fully deleted/destroyed after the above time periods except that FMI Inc. may further process certain information in fully anonymised form (i.e., without such information being directly or indirectly attributable to your person), as set out in Section 2 below.

## F. General Data Protection Information

The information in Section 3 ("General Data Protection Information") forms an integral part of this consent and provides further details about the processing of your personal data and your rights.

## Section 2 (Optional Consent) –

### Consent to the Processing of your Pseudonymised Data and Residual Material for Research and Scientific Purposes

If you give your consent by providing your signature at the end of this form, your pseudonymised data and any residual material will also be used by FMI, including in a commercial context, for research and scientific purposes to improve the understanding of tumour genesis and tumour progression and to facilitate the improvement, validation and development of new diagnostic and therapeutic approaches for the treatment of genetic diseases. Your consent to the processing of your personal data and use of your residual material as described in this Section 2 is voluntary, and you can freely decide whether and to what extent you wish to grant your consent.

### A. Processing of Pseudonymised Data and Residual Material for Research and Scientific Purposes

Where you provide your consent to the processing of your pseudonymised data and residual material by signing Section 2 (Optional Consent) of this Patient Consent Form, you agree that FMI GmbH and FMI Inc. will, as joint controllers:

- store (i) any data received and/or generated as part of providing the Service (i.e., Test Requisition Form Data, scanned tissue slides, sequencing data, supplementary molecular information if applicable) together with the prepared report and (ii) any residual material received, other than any tumour block, and/or generated as part of providing the Service (e.g. extracted DNA/RNA) for research and scientific purposes for a maximum period of 10 years after the Completion of the Service and discarded thereafter. FMI will store your data and residual material only in pseudonymised form (under the Order-ID) and will not receive or store your name or other information which would be directly attributable to your person. For the avoidance of doubt, any residual material available as tumour block and not fully used up will be returned to your pathologist;
- process such data and residual material in pseudonymised or anonymised form, including in a commercial context, for research and scientific purposes, including statistical analysis, to further understand the causes for tumour genesis and tumour progression as well as to improve, validate and/or develop new diagnostic and therapeutic approaches for the treatment of genetic diseases, including to improve the Services FoundationOne CDx, FoundationOne Liquid CDx and FoundationOne Heme; and
- disclose such data and provide the residual material for the above purposes in pseudonymised or anonymised form, including in a commercial context, to external academic, industrial or other collaboration partners. Your residual material will only be disclosed in a de-identified form without any additional information which could either directly or indirectly be attributed to your person.

Your personal data and residual material will not be used for any other purposes, except in fully anonymised form (i.e., where the information has been rendered anonymous so that it can no longer in any way (neither directly nor indirectly) be attributed to your person).

### B. General Data Protection Information

The information in Section 3 ("General Data Protection Information") forms an integral part of this consent and provide further details about the processing of your personal data and your rights.

## Section 3 – General Data Protection Information

The following general data protection information applies to all data processing activities described in Sections 1 and 2.

### A. Contact Details; Data Protection Officer

**Local Roche Affiliate:** Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW, UK.

---

#### Roche Products Limited

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden  
City, Hertfordshire AL7 1TW,  
Registered in England 100674  
medinfo.uk@roche.com

Roche Products Limited is the sole licensed distributor of  
Foundation Medicine, Inc. products in the UK

M-GB-000001765 November 2020

**Roche Pharma AG:** Roche Pharma AG, Emil-Barell-Straße 1, 79639 Grenzach, Germany

**FMI GmbH:** Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

**FMI Inc.:** Foundation Medicine Inc., 150 Second Street, Cambridge, MA 02141, USA

The data protection and privacy officers of Roche and FMI are your points of contact regarding any questions, suggestions or complaints concerning the processing of your personal data.

Their contact details are as follows:

**Data protection officer of Roche Affiliate:**

Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW, UK

[dpo.dpowlwyn@roche.com](mailto:dpo.dpowlwyn@roche.com), Phone: +44 (1707) 366 000

**Data protection officer of Roche Pharma AG:**

Roche Pharma AG, Emil-Barell-Straße 1, 79639 Grenzach, Germany,

[grenzach.datenschutz.gd1@roche.com](mailto:grenzach.datenschutz.gd1@roche.com), Phone: +49 (7624) 14-2829

**Data protection officer of FMI GmbH:**

Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany;

[dpo.fmi-germany@foundationmedicine.com](mailto:dpo.fmi-germany@foundationmedicine.com), Phone: +49 (8856) 905-3715

**Data protection officer of FMI Inc:**

Foundation Medicine, Inc.,

150 Second Street, Cambridge, Massachusetts 02141,

[dpo.fmi-cambridge@foundationmedicine.com](mailto:dpo.fmi-cambridge@foundationmedicine.com), Phone: +1(617) 413-7313

## B. Security

Roche and FMI take appropriate technical and organisational measures to protect your personal data against accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to, personal data transmitted, stored or otherwise processed.

## C. Your Rights

You have the right, in accordance with applicable data protection law,

- to request information about the data processed about you, and to obtain a copy of such data (right of access);
- to obtain the rectification of inaccurate data or, taking into account the purposes of the processing, request the completion of incomplete data (right to rectification);
- to obtain the erasure of personal data to the extent one of the grounds provided for by statutory law applies (right to be forgotten);
- to the extent the statutory requirements are fulfilled, to obtain the restriction of processing of your data (right to restriction of processing);
- to the extent the statutory requirements are fulfilled, to receive any personal data you provided to Roche and/or FMI in a structured, commonly used and machine-readable format and to transmit those data to another controller or, where technically feasible, have the data transmitted (right to data portability); and
- not to be subject to an automated individual decision making if the statutory requirements are not fulfilled. An automated individual decision-making is not taking place.

You further have the right to object, on grounds relating to your particular situation and in accordance with applicable law, to any processing of your personal data based on the ground that the processing is necessary for purposes of legitimate interests pursued by Roche and/or FMI (right to object).

You further have the right to withdraw your consent at any time without affecting the lawfulness of processing based on consent before its withdrawal.

To exercise your rights, please contact your treating physician. You may also contact any of the data protection officers named above under Section 3. A. Please note, however, that FMI generally only receives pseudonymised data and therefore neither a verification of your authorisation nor an identification of your person or the data concerning you can be ensured in the context of your requests without receiving additional information from you and your treating physician or pathologist. Therefore, in order to effectively exercise your rights (and to avoid having to identifying yourself to FMI), please contact your treating physician or pathologist directly, even if you wish to exercise your rights against FMI GmbH and/or FMI Inc.

You further have the right to lodge a complaint with a data protection authority, in particular the data protection authority competent for your place of habitual residence or place of the alleged infringement.

---

### Roche Products Limited

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden  
City, Hertfordshire AL7 1TW,  
Registered in England 100674  
[medinfo.uk@roche.com](mailto:medinfo.uk@roche.com)

Roche Products Limited is the sole licensed distributor of  
Foundation Medicine, Inc. products in the UK

# Patient Information (and Declaration of Consent) to the Processing of Personal Data For FoundationOne® CDx, FoundationOne® Heme or FoundationOne® Liquid CDx

**IMPORTANT NOTE:** Please provide your consent on two (2) original copies of this document and return one (1) to your treating physician; the other copy is for your records. **Please do not return a copy of this document to Roche.**

## Consent to the Processing of my Personal Data in accordance with Section 1.

I hereby consent to the processing of my personal data, including my health data, as specified in Section 1 above for the purpose of providing the requested Service (as indicated at the top of this Patient Consent Form), including the transfer of my personal data to FMI Inc. in the US. I am aware that I am not obliged to provide this consent and that I may withdraw this consent at any time by contacting my treating physician. I may also contact any of the data protection officers named under Section 3 A. The withdrawal of my consent does not affect the lawfulness of any processing based on my consent before its withdrawal.  
If I withdraw my consent, the requested Service will be deemed to be terminated and will be stopped at its then current stage. Roche will be released from its duty to perform the Service.  
I am free to provide my consent. However, if I do not grant my consent, the Service cannot be provided.

## Consent to the Processing of my Personal Data in accordance with Section 2.

I hereby consent to the processing of my personal data, including my health data, and residual material by FMI, including in a commercial context, for research and scientific purposes as specified in Section 2 above. I am aware that I am not obliged to provide this consent and that I may withdraw this consent at any time by contacting my treating physician. I may also contact any of the data protection officers named under Section 3 A. The withdrawal of my consent does not affect the lawfulness of any processing based on such consent before its withdrawal. I understand that even in case I withdraw my consent, FMI will continue to process any data and/or residual material already fully anonymised by FMI before the withdrawal.  
I am free to provide my consent to the above. If do not provide consent , or I withdraw my consent at a later time, such withdrawal will not affect the provision of the requested Service.

Place / Date

Patient Name (in capital letters)

---

Patient's signature\*

\* To be signed by the legal guardian in the case of minors

---

**Roche Products Limited**

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW,  
Registered in England 100674  
medinfo.uk@roche.com

Roche Products Limited is the sole licensed distributor of Foundation Medicine, Inc. products in the UK

M-GB-000001765 November 2020